Coronaviruses and influenza viruses pose a major risk to global health, underscored by the impact of the COVID-19 pandemic and continuing spread of SARS-CoV-2 variants.

The National Institute of Allergy and Infectious Diseases (NIAID) Collaborative Influenza Vaccine Innovation Centers (CIVICs) program is addressing critical gaps in the prevention and control of influenza